TABLE 2.
DSA characteristics in patients with early-DSA and late-DSA.
| DSA characteristics | Early-DSA (n = 30) | Late-DSA (n = 19) | p |
|---|---|---|---|
| Class of DSA (n, %) • Class-I • Class-II a • Both class-I and class-II a |
17 (56.7%) 10 (33.3%) 3 (10.0%) |
6 (31.6%) 10 (52.6%) 3 (15.8%) |
0.230 |
| Number of DSA per patient: >1 DSA in the first sample (n, %) | 10 (33.3%) | 7 (36.8%) | 0.801 |
| “Transient” DSA (n, %) | 20 (66.7%) | 7 (36.8%) | 0.041 |
| MFI at DSA first occurrence b | 4912.0 (2505.7–7235.2) | 2428.5 (1432.5–11,109.0) | 0.365 |
| IS at the time of first DSA detection • Tacrolimus (n, %) • MMF/MPA (n, %) • Prednisone (n, %) • mTORi (n, %) |
29 (96.7%) 29 (96.7%) 29 (96.7%) 0 (0.0%) |
18 (94.7%) 18 (94.7%) 17 (89.5%) 2 (10.5%) |
0.739 0.739 0.306 0.070 |
| ABMR (Banff 2019 Classification) (n, %) • ABMR before DSA detection • ABMR at the time/after DSA detection Time from DSA to ABMR diagnosis (months) b |
16 (53.3%) 5 (31.3%) 11 (68.8%) 1.4 (0.3–3.1) |
15 (78.9%) 7 (46.7%) 8 (53.3%) 3.2 (2.0–5.2) |
0.070 0.370 |
a
Of patients with class-II DSA, in both groups (alone or together with class-I DSA), 18/26 (69.2%) had anti-DQB, 5/26 (19.2%) had anti-DQA, and 1/16 (3.8%) had anti-DP DSA.
b
Median and interquartile range. For continuous variables with non-normal distribution, the Mann-Whitney U test was used to compare the 2 groups.
DSA: donor-specific HLA, antibody. MFI: mean fluorescence intensity. IS: immunosuppression. MMF/MPA: Mycophenolate mofetil/Mycophenolic acid. mTORi: mTOR, inhibitor.